$STSS is now in the commercial stage, shifting from R&D to generating real revenue. In mid-2025, we completed our first product shipments to customers in the U.S. and Europe, officially marking the start of sales for our SoloGard, SecureGard, and low-dead-space syringes. #Nasdaq
At $STSS, we are not just manufacturing syringes, collaboration is at our core. We work closely with healthcare providers and pharmaceutical companies to build a smarter, more secure future for healthcare delivery. #SharpsTechnology#STSS#NASDAQ#SmartSyringes#MedicalDevices
As we celebrate the values of freedom, innovation, and resilience, we are grateful for the opportunity to support our customers, partners and stakeholders every day.
Happy Independence Day from all of us at Sharps Technology! $STSS
#SharpsTechnology#Nasdaq#STSS#FourthOfJuly
Sharps Technology (NASDAQ: STSS) announced that a 2nd commercial delivery is underway for its $50 million SoloGard™ supply agreement, and also begins manufacturing facility upgrades.
https://t.co/5Rph9RlQ5Z
#STSS#NASDAQ#SharpsTechnology#Healthcare#BioTech#MedicalDevices